Clinical Results of High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation in Children with Advanced Stage Rhabdomyosarcoma.
10.3346/jkms.2012.27.9.1066
- Author:
Nam Kyun KIM
1
;
Hyo Sun KIM
;
Chang Ok SUH
;
Hyun Ok KIM
;
Chuhl Joo LYU
Author Information
1. Department of Pediatrics, Yonsei University Health System, Seoul, Korea. cj@yuhs.ac
- Publication Type:Original Article
- Keywords:
Rhabdomyosarcoma;
Children;
Chemotherapy;
Bone Marrow Transplantation
- MeSH:
Adolescent;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Carboplatin/administration & dosage;
Child;
Child, Preschool;
Disease-Free Survival;
Etoposide/administration & dosage;
Female;
Humans;
Ifosfamide/administration & dosage;
Infant;
Male;
*Peripheral Blood Stem Cell Transplantation;
Retrospective Studies;
Rhabdomyosarcoma/*drug therapy/mortality/pathology;
Survival Rate;
Transplantation, Autologous;
Treatment Outcome
- From:Journal of Korean Medical Science
2012;27(9):1066-1072
- CountryRepublic of Korea
- Language:English
-
Abstract:
Regardless of improvement in cure of Rhabdomyosarcoma (RMS), the results in treatment of advanced stage of RMS in children are still dismal. Recently, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/APBSCT) has been tried to manage the advanced high-risk RMS patients. We investigated the effectiveness of HDC/APBSCT by reviewing the clinical records of high-risk pediatric RMS patients in single institute database. Over twenty years, 37 patients were diagnosed as RMS with high-risk at the time of first diagnosis. These patients were classified as two groups according to treatment method. The first group was HDC/APBSCT and the other was conventional multi-agent chemotherapy group. Differences of clinical results between the two groups were analyzed. The median age of patients was 5 yr, ranging from 6 months to 15 yr. The 5-yr event free survival rate (EFS) of all patients was 24.8% +/- 4.8%. HDC/APBSCT group and conventional multi-agent chemotherapy group were 41.3% +/- 17.8% and 16.7% +/- 7.6% for 5-yr EFS, respectively (P = 0.023). There was a significant difference in the result of HDC/APBSCT between complete remission or very good partial response group and poor response group (50% +/- 20.4% vs 37.5% +/- 28.6%, P = 0.018). HDC/APBSCT can be a promising treatment modality in high-risk RMS patients.
